This is not a pharma story. It is a volume story. Knees still get replaced, hips still get repaired, and procedure tools still get used even when the market is in a bad mood.
The Wealth Strategy (Sponsored)
His official salary? $400,000 a year.
Yet his returns point to something far bigger:
Up to $250,000 per month… from just one place.
It’s not property.
It’s not equities.
So what’s really generating this kind of income — and why is it gaining traction now?
Find out how to get started for under $20
Theme: Orthopedics and Procedure Devices
This setup works because the demand is hard to cancel. A patient can postpone a procedure. They usually do not postpone it forever.
That gives the device makers a steadier volume backdrop than a lot of investors assume.
What’s Driving It
The group still has real momentum.
Globus Medical reported Q4 2025 worldwide net sales of $826.4 million, up 25.7%, and full-year 2025 revenue of $2.939 billion, up 16.7%. It guided 2026 revenue to $3.184 billion to $3.222 billion and non-GAAP EPS to $4.40 to $4.50.
Stryker had already scheduled Q1 2026 results for April 30, and Zimmer Biomet had scheduled Q1 2026 results for April 28, which keeps both names right in the earnings window for this theme.
Here is the chain reaction:
Procedure demand stays active → implant and device volume stays healthy
Volume stays healthy → fixed-cost leverage improves margins
Margins improve → earnings recover faster than revenue
Earnings improve → the market rewards the cleaner operators
What’s Working
The biggest positive right now is that procedure-driven medtech still looks like a real business, not a hope trade. The market is rewarding companies that can show volume, pricing discipline, and solid guidance.
Globus already has the strongest current number set in the basket, and the bigger names still benefit from hospitals staying busy enough to keep core procedures moving.
What to Watch
You should watch volume, margin, and guidance more than headlines.
This is a category where the story can look great right up until a company posts a soft quarter on pricing, hospital purchasing, or mix. The premium names usually get hit hardest when expectations outrun the numbers.
Stryker (SYK)
What it does: Orthopedics, medical-surgical tools, neurotechnology, and hospital equipment.
Why it fits: Stryker is the quality anchor in this basket. It had already scheduled Q1 2026 results for April 30, which keeps it front and center for a procedure-volume theme.
Investors usually treat it as the cleanest operator in the group for a reason: scale, execution, and broad category exposure.
What stands out: You are not buying Stryker for one product cycle. You are buying it because it tends to execute across multiple categories at once.
That makes it the lowest-drama way to play this theme.
What to watch: Watch the Q1 print for procedure volume, pricing, and whether management still sounds confident without needing to stretch.
The Takeaway: Buy this first if you want the highest-quality device name and the cleanest way to play procedure demand.
The risk is that the premium multiple leaves no room for a soft quarter.
Zimmer Biomet (ZBH)
What it does: Orthopedic implants and musculoskeletal healthcare products.
Why it fits: Zimmer gives you a more direct orthopedics bet. It had already scheduled Q1 2026 results for April 28, which makes it one of the most timely names in the basket this week.
What stands out: This is the more focused joint-replacement name. If you want pure exposure to orthopedic procedure demand instead of a broader medtech mix, this is the cleaner lane.
What to watch: The Q1 release matters. You want sales growth, procedure commentary, and signs that execution is getting stronger, not just stable.
The Takeaway: Buy this if you want a direct orthopedics bet with room to rerate on a good quarter.
The risk is that a flat print keeps the stock stuck as a slower-growth device name.
Data Raises Questions (Sponsored)
Confirmed by satellites 300 miles above the Earth's surface...
Elon Musk is rolling out a breakthrough technology that could replace our need for foreign oil and ignite a $10 trillion boom a small group of stocks.
Click here to learn how you can invest in this before it becomes mainstream.
Smith & Nephew (SNN)
What it does: Orthopedics, sports medicine, wound care, and related procedure products.
Why it fits: Smith & Nephew gives you a broader procedure-device angle than a pure implant company. That matters if you want this theme without relying entirely on one narrow orthopedic lane.
What stands out: You are getting exposure to multiple categories tied to hospital and procedure activity.
If execution improves, that broader product mix can help the stock look better than a pure implant name with less room to hide.
What to watch: Watch margin progress and whether the business starts looking more like a recovering operator than a permanent repair job.
The Takeaway: Buy this only if you want broader procedure exposure and believe the turnaround still has room.
The risk is that execution stays uneven and the market keeps treating it like the weaker cousin in the group.
Globus Medical (GMED)
What it does: Musculoskeletal implants, spine products, enabling technologies, and orthopedic procedure tools.
Why it fits: Globus has the strongest current number set in the basket. Q4 2025 worldwide net sales rose 25.7% to $826.4 million, and 2026 guidance points to another year of growth.
That gives you actual momentum, not just a quality reputation.
What stands out: This is the stock with the clearest operating momentum right now. If you want a name where the growth is already showing up in the numbers, this is the one.
What to watch: Watch margins and execution. Once a company posts this kind of growth and guidance, investors stop being patient with any stumble.
The Takeaway: Buy this if you want the strongest current operating momentum in the basket.
The risk is that any miss on execution or margin follow-through gets punished quickly because expectations are now higher.
AI Alert (Sponsored)
Elon Musk could take SpaceX public in 2026, at an estimated $1.75 trillion valuation.
The IPO would include Elon's AI model, Grok. But according to Louis Navellier, a radical new AI model will launch this year… over 1,000 times more powerful than Elon's.
And the company behind it could outperform SpaceX in the process.
Click here for full details (including Louis' new pick — free).
*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.
Poll: What do you think is the most underrated investment story of 2026 so far?
Edwards Lifesciences (EW)
What it does: Structural heart devices and procedure-driven cardiovascular technologies.
Why it fits: Edwards broadens the theme beyond knees and hips. It gives you procedure-device exposure tied to structural heart and cardiac interventions, which makes the basket less one-dimensional.
What stands out: This is the more specialized, higher-quality medtech angle. If procedure demand stays active, Edwards gives you a cleaner growth profile than some of the slower orthopedic names.
What to watch: Watch procedure volume, market-share commentary, and whether the growth profile still supports the premium investors give it.
The Takeaway: Own this if you want the cleaner, higher-quality procedure-device story outside straight orthopedics.
The risk is that slower procedure growth compresses the premium multiple fast.
Elite Trade Club Insider
$11 Million Just Came Out Of One CEO’s Stock
A CEO sold a combined $11.2 million worth of stock across three straight sessions. On the flip side, a healthcare giant saw a $2.7 million proposed sale and a fresh $201,300 buy from its CFO. The full breakdown is inside today’s Insider section.
You’re reading the free version. Here’s what we held back.
Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.
A subscription gets you:
The insider buys, options bets, and dark pool moves the free edition can't show you. Unlocked every weekday.
A Sunday Deep Dive that tells you where to look before Monday's bell rings.
The Friday Smart Money Brief: who bought, who sold, where the big options bets landed, and where institutions are hiding volume. Three data layers. One email.
A Monthly Insider Scorecard so you always know whether smart money is buying or selling the market.
Every past Insider edition, unlocked, on elitetrade.club. Go back and see what you missed.
$25/mo or $250/yr. 30-day money-back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.
This theme works because people can delay discomfort only so long. Procedure volume does not need to explode.
It just needs to stay active enough for the best operators to keep converting demand into margins. Focus on the names with clean guidance, strong execution, and enough scale to handle a choppy quarter without losing the plot.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
